Tag: GlobeNewswire

CHATTANOOGA, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) — Astec Industries, Inc. (NASDAQ: ASTE) announced that its Board of Directors declared a quarterly dividend of $0.13 per share. The dividend is to be paid on or about December 4, 2026, to shareholders of record as of the close of business on November 16, 2026.

About Astec

Astec, (www.astecindustries.com), is a manufacturer of specialized equipment for asphalt road building, aggregate processing and concrete production. Astec’s manufacturing operations are divided into two primary business segments: Infrastructure Solutions that includes road building, asphalt and concrete plants, thermal and storage solutions; and Materials Solutions that include our aggregate processing equipment. Astec also operates a line of controls and automation products designed to deliver enhanced productivity through improved equipment performance.

For more information, visit astecindustries.com and follow us on social media.

LinkedIn https://www.linkedin.com/company/astecindustries/
Facebook https://www.facebook.com/astecindustries
Instagram https://www.instagram.com/astec_industries/
YouTube https://www.youtube.com/@astec6306/featured
Twitter @astecindustries

Contact:

Stephen C. Anderson
Senior Vice President, Investor Relations
sanderson@astecindustries.com
+1 (423) 899-5898
www.astecindustries.com

– CASGEVY^® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 –

– CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older –

– FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310^® for severe hypertriglyceridemia and elevated LDL-C –

– Phase 1b data for CTX310 in severe hypertriglyceridemia to be presented in a late-breaking oral presentation at AHA Scientific Sessions 2026; Phase 1 data for zugo-cel in systemic sclerosis to be presented at ACR Convergence 2026 –

– Completed enrollment in the Phase 2 clinical trial of CTX611 in patients undergoing total knee arthroplasty –

– Appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer and A.J. Silver as Chief Financial Officer –

ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the third quarter ended September 30, 2026.

“The third quarter marked meaningful progress for CRISPR Therapeutics,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA’s RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease. With new clinical data from CTX310 and zugo-cel in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we are entering a pivotal period for our pipeline.”

Recent Highlights and Outlook

Hemoglobinopathies and CASGEVY^® (exagamglogene autotemcel)

• CASGEVY, the world’s first approved CRISPR-based therapy, has been shown to reduce or eliminate vaso-occlusive crises (VOCs) in eligible patients with sickle cell disease (SCD) and transfusion requirements in eligible patients with transfusion-dependent beta thalassemia (TDT). CASGEVY is approved in 39 countries across North America, Europe, and the Middle East for eligible patients 12 years of age and older, with approvals for younger children in five of those countries.
• CASGEVY generated third quarter 2026 revenue of $99 million, representing 30% growth quarter-over-quarter and nearly six times the revenue reported in the third quarter of 2025. Twice as many in the first nine months of 2026 as in all of 2025, and more than 750 patients have initiated treatment worldwide.
• CASGEVY’s availability for younger patients continues to expand. In July, the FDA approved CASGEVY for children 2 years of age and older with SCD or TDT, making it the first genetic therapy for SCD and TDT approved for this age group, and multiple children have since initiated treatment in the U.S. The Kingdom of Saudi Arabia, the United Arab Emirates, and the Kingdom of Bahrain have also approved CASGEVY for children 2 years of age and older, and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved CASGEVY for children 5 years of age and older with severe SCD or TDT.
• Building on CASGEVY, CRISPR Therapeutics is advancing an in vivo hematopoietic stem cell editing approach that could extend gene editing to many more patients with SCD and TDT. Using lipid nanoparticle (LNP)-mediated delivery, the approach is designed to edit stem cells directly in the body, potentially simplifying treatment and broadening global access.

In Vivo Liver Editing

CRISPR Therapeutics continues to advance a diversified portfolio of in vivo gene editing programs leveraging its proprietary liver-directed LNP delivery platform.

• The Phase 1 clinical trial of CTX310^®, targeting angiopoietin-related protein 3 (ANGPTL3) is ongoing.
• CRISPR Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for the treatment of severe hypertriglyceridemia (sHTG) and for the treatment of patients with elevated LDL-C. RMAT designation provides the benefits of Fast Track and Breakthrough Therapy designations, including early interactions with the FDA and potential eligibility for priority review and accelerated approval.
• In August, CRISPR Therapeutics presented Phase 1a durability data for CTX310 in a late-breaking session at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in The New England Journal of Medicine. A single course treatment of CTX310 produced deep and durable reductions in circulating ANGPTL3, triglycerides (TG), and low-density lipoprotein (LDL) that were sustained through one year of follow-up. At the highest dose, the mean reductions from baseline were 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL-C in a mixed patient cohort with high triglycerides, high LDL-C, or both. CTX310 was well tolerated with no treatment-related serious adverse events.
• Phase 1b data in patients with sHTG will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026 on November 9, 2026, at 8:00 a.m. CT. 
• The Phase 1 clinical trial of CTX340™, targeting angiotensinogen (AGT), in patients with refractory hypertension is ongoing.
• The Phase 1 clinical trial of CTX460™, targeting SERPINA1 for alpha-1 antitrypsin deficiency (AATD), is ongoing. CTX460 is the first investigational candidate from the Company’s SyNTase™ editing platform.
• CTX321™, the Company’s next-generation LPA program, is progressing through IND/CTA-enabling studies.

siRNA-based Programs

CRISPR Therapeutics’ small interfering RNA (siRNA)-based portfolio, developed in collaboration with Sirius Therapeutics, includes programs targeting cardiovascular and thromboembolic diseases.

• CRISPR Therapeutics has completed enrollment in the Phase 2 clinical trial of CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI), in patients undergoing total knee arthroplasty (TKA), with an update expected in the second half of 2026. CTX611 has potential across a broad range of thromboembolic indications. CRISPR Therapeutics will lead global Phase 3 development, with Sirius Therapeutics overseeing development in greater China.
• CRISPR Therapeutics has the option to nominate up to two additional siRNA targets, with an update expected in 2027.

Autoimmune Disease and Immuno-Oncology

Zugocabtagene geleucel (zugo-cel; formerly CTX112™) continues to advance across both autoimmune disease and hematologic malignancies.

• In autoimmune disease, zugo-cel is being evaluated in three ongoing Phase 1 trials: a rheumatology basket including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM); a hematology basket in immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA); and a trial in autoimmune neurologic diseases, including progressive multiple sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), N-methyl-D-aspartate receptor (NMDAR) and leucine-rich glioma-inactivated protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff person syndrome (SPS). Enrollment is ongoing globally.
• Phase 1 clinical data in patients with refractory SSc will be presented in a poster presentation at the American College of Rheumatology (ACR) Convergence 2026 on November 8 at 10:30 a.m. ET.
• In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell malignancies is ongoing, with updates anticipated in the second half of 2026. A combination study evaluating zugo-cel with pirtobrutinib in aggressive B-cell lymphomas, under the Company’s existing collaboration with Lilly, is also ongoing.

CRISPR Therapeutics is also advancing a proprietary in vivo CAR-T platform with potential applications across autoimmune disease and oncology.

The Company is pursuing two modalities, supported by an antibody-conjugated LNP delivery system targeting immune cells: a transient, re-dosable mRNA-based CAR-T and a non-viral, integrating CAR-T, for which the Company is evaluating multiple integration approaches. Both programs are in the IND/CTA-enabling phase, focused on a best-in-class profile.

Regenerative Medicine

• The Company is developing CTX213™, a deviceless beta cell replacement candidate for Type 1 diabetes, consisting of unencapsulated precursor islet cells derived from edited induced pluripotent stem cells (iPSCs). CTX213 has demonstrated compelling preclinical efficacy through direct administration and is progressing toward the clinic.

Other Corporate Matters

• Earlier today, CRISPR Therapeutics announced the appointment of Sivakesava Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings more than 30 years of technical operations and quality leadership across biologics, vaccines, oligonucleotides, RNA therapeutics, and LNP delivery, most recently as Chief Technical Officer at Orna Therapeutics.
• In October, CRISPR Therapeutics announced the appointment of A.J. Silver, the Company’s Senior Vice President of Finance, as Chief Financial Officer, effective October 19, 2026, succeeding Raju Prasad, Ph.D., who stepped down to pursue external opportunities.
• The Company’s in vivo and cell therapy programs are supported by a wholly-owned GMP manufacturing facility in Framingham, Massachusetts. The facility provides end-to-end production capabilities, supports both clinical and future commercial supply, and enables an industry-leading cost of goods.

Third Quarter 2026 Financial Results  

• Cash Position: Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared to $1,975.8 million as of December 31, 2025. The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses.
• R&D Expenses: R&D expenses were $71.9 million for the third quarter of 2026, compared to $58.9 million for the third quarter of 2025. The increase in R&D expense was primarily attributable to an increase in external research and development expenses and sublicense fees, offset by a decrease in employee-related costs.
• Acquired In-Process R&D Expenses: Acquired in-process R&D expenses were $11.7 million for the third quarter of 2026. Acquired in-process R&D expenses for the third quarter of 2026 primarily consisted of a development milestone under the Sirius Agreement that was recognized in the third quarter of 2026. No acquired in-process R&D expenses were recognized during the third quarter of 2025.
• G&A Expenses: General and administrative expenses were $17.9 million for the third quarter of 2026, compared to $16.9 million for the third quarter of 2025.
• Collaboration Expense: Collaboration expense, net, was $41.3 million for the third quarter of 2026, compared to $57.1 million for the third quarter of 2025. The decrease was primarily attributable to an increase in the Company’s share of CASGEVY revenue.
• Net Loss: Net loss was $111.4 million for the third quarter of 2026, compared to a net loss of $106.4 million for the third quarter of 2025.

About CASGEVY^® (exagamglogene autotemcel [exa-cel])

CASGEVY^® is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT), in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world, and for younger children in select countries.

About the CRISPR Therapeutics – Vertex Collaboration for CASGEVY

CRISPR Therapeutics and Vertex established a strategic research collaboration in 2015 to discover and develop therapies leveraging CRISPR/Cas9 technology to address the underlying genetic causes of human disease. CASGEVY is the first approved therapy to emerge from this collaboration. Under an amended agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis. Vertex is the manufacturer and exclusive license holder of CASGEVY.

About In Vivo Liver Editing Programs

CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and its novel, proprietary SyNTase™ editing technology. The Company’s in vivo portfolio includes three cardiovascular programs: CTX310, targeting angiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia; CTX340, targeting angiotensinogen (AGT), in development for refractory hypertension; and CTX321, targeting LPA, in development for patients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company’s disclosed development candidates also include CTX460™, targeting SERPINA1 using SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency (AATD).

About CTX611 (SRSD107)

CTX611 is a novel double-stranded, long-acting siRNA, designed to target the human coagulation factor XI, or FXI, messenger RNA and inhibit FXI protein expression. Through modulation of the intrinsic coagulation pathway, CTX611 is intended to provide anticoagulant and antithrombotic effects with a decreased risk of bleeding compared to other anti-thrombotics. Supported by clinical experience conducted by Sirius Therapeutics in two Phase 1 clinical trials, the Company and Sirius Therapeutics are developing CTX611 as a long-acting FXI inhibitor with the potential to support infrequent, including semi-annual, subcutaneous administration.

About the CRISPR Therapeutics – Sirius Therapeutics Collaboration for siRNA

CRISPR Therapeutics and Sirius Therapeutics entered into a strategic collaboration in 2025 to develop and commercialize siRNA therapies for thromboembolic disorders and other serious diseases. The lead program, CTX611, is a long-acting siRNA targeting FXI, which the companies will co-develop on an equal cost-and-profit-sharing basis. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will lead commercialization in greater China. The collaboration also provides CRISPR Therapeutics with the option to license up to two additional siRNA programs.

About Zugocabtagene Geleucel (zugo-cel; formerly CTX112)

Zugocabtagene geleucel (zugo-cel) is a wholly-owned, allogeneic chimeric antigen receptor (CAR) T cell therapy product candidate targeting Cluster of Differentiation 19 (CD19), in development for both autoimmune and immuno-oncology indications. The off-the-shelf therapy leverages CRISPR/Cas9 for targeted gene knockout and CAR insertion, enabling immune evasion and enhanced T effector cell potency, and is administered following a standard lymphodepletion regimen without the need for human leukocyte antigen (HLA) matching. In autoimmune disease, zugo-cel is being investigated in three ongoing basket trials. The rheumatology basket trial is enrolling adult patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM). The hematology basket trial is enrolling patients with immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA). The neuroimmune basket trial is enrolling patients with progressive multiple sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated Disease (MOGAD), N-methyl-D-aspartate receptor (NMDAR) and leucine-rich glioma-inactivated Protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff person syndrome (SPS). In immuno-oncology, zugo-cel is being investigated in a trial in adult patients with relapsed or refractory B-cell malignancies.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY^® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

CRISPR THERAPEUTICS^® standard character mark and design logo, CTX112™, CTX213™, CTX310^®, CTX321™, CTX340™, CTX460™, CTX611™ and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY^® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.

CRISPR Special Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements made by Dr. Kulkarni in this press release, as well as regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) data included in this press release, as well as the ability to use data from ongoing and planned studies and clinical trials for the design and initiation of further studies and clinical trials; (iii) CRISPR Therapeutics strategy, goals, anticipated financial performance and the sufficiency of its cash resources; (iv) plans and expectations for the commercialization of and anticipated benefits of CASGEVY, including anticipated patient access to CASGEVY; (v) regulatory submissions and authorizations, including timelines for and expectations regarding regulatory agency decisions; (vi) the expected benefits of its collaborations; and (vii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9 and SyNTase, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

This press release also contains information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from market research firms and other third parties, including medical publications, government data and similar sources. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. This press release discusses investigational therapies and is not intended to convey conclusions about efficacy or safety as to those investigational therapies or uses of such investigational therapies. There is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities.

Investor Contact:
+1-617-307-7503
ir@crisprtx.com

Media Contact:
+1-617-315-4493
media@crisprtx.com

CRISPR Therapeutics AG Condensed Consolidated Statements of Operations (Unaudited, In thousands except share data and per share data)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue:
Collaboration revenue		$	12,323			$	—			$	23,323			$	—
Grant revenue			346				889				985				2,646
Total revenue			12,669				889				24,308				2,646
Operating expenses:
Research and development			71,888				58,902				207,614				201,280
Acquired in-process research and development			11,675				—				14,148				96,253
General and administrative			17,867				16,931				52,603				55,143
Collaboration expense, net			41,284				57,115				127,505				159,777
Total operating expenses			142,714				132,948				401,870				512,453
Loss from operations			(130,045	)			(132,059	)			(377,562	)			(509,807	)
Total other income, net			18,682				26,237				53,913				61,841
Net loss before income taxes			(111,363	)			(105,822	)			(323,649	)			(447,966	)
Provision for income taxes			(74	)			(619	)			(1,873	)			(3,020	)
Net loss			(111,437	)			(106,441	)			(325,522	)			(450,986	)
Foreign currency translation adjustment			2				(28	)			(20	)			94
Unrealized (loss) gain on marketable securities			(9,456	)			973				(18,884	)			3,052
Comprehensive loss		$	(120,891	)		$	(105,496	)		$	(344,426	)		$	(447,840	)
Net loss per common share — basic		$	(1.15	)		$	(1.17	)		$	(3.38	)		$	(5.12	)
Basic weighted-average common shares outstanding			96,741,070				91,305,337				96,437,995				88,124,241
Net loss per common share — diluted		$	(1.15	)		$	(1.17	)		$	(3.38	)		$	(5.12	)
Diluted weighted-average common shares outstanding			96,741,070				91,305,337				96,437,995				88,124,241

CRISPR Therapeutics AG Condensed Consolidated Balance Sheets Data (Unaudited, in thousands)
		As of
		September 30, 2026				December 31, 2025
Cash and cash equivalents		$	192,027			$	347,559
Marketable securities			2,080,521				1,628,269
Marketable securities – non-current			4,021				—
Working capital			2,144,117				1,836,551
Total assets			2,556,412				2,265,243
Total shareholders’ equity			1,648,068				1,921,813

MIDLAND, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback,” “we,” “our” or the “Company”) today announced financial and operating results for the third quarter ended September 30, 2026.

THIRD QUARTER 2026 HIGHLIGHTS

• Average oil production of 525 MBO/d (1,034 MBOE/d)
• Net cash provided by operating activities of $2.6 billion; Operating Cash Flow Before Working Capital Changes¹ of $3.2 billion
• Cash capital expenditures of $1.0 billion
• Free Cash Flow¹ and Adjusted Free Cash Flow¹ of $2.1 billion and $2.2 billion, respectively
• Increased annual base dividend by 7.3% to $4.72 per share; marks an 18% year over year increase and a ~2.2% annualized yield²
• Repurchased 1.3 million shares of common stock for approximately $251 million
• Repurchased $106 million in aggregate principal amount of 2054 and 2064 Senior Notes at a weighted average price of 94.9% of par ($103 million, including accrued interest)
• Acquired a 7.5% equity interest in the Solitude Pipeline System, a Permian-to-Katy natural gas pipeline

____________________________________
_{¹ NON-GAAP DISCLOSURES – For a definition of Operating Cash Flow Before Working Capital Changes, Free Cash Flow, Adjusted Free Cash Flow, Adjusted Net Income, Adjusted EBITDA, Adjusted Net Income per Diluted Share, Net Debt and reconciliations of such non-GAAP financial metrics to their respective most directly comparable GAAP metrics, please see “Non-GAAP Financial Measures” below.
² Cash dividend payable on November 19, 2026; annualized yield based on October 30, 2026 closing share price of $212.08}

UPDATED 2026 GUIDANCE HIGHLIGHTS

• Increasing annual oil production guidance to ~524 (from 522+) MBO/d with total BOE production of ~1,015 (from 1,000+) MBOE/d and full year cash capital expenditures to $3.95 – $4.00 billion (from ~$3.9 billion)
• Q4 2026 oil production guidance of 518 – 528 MBO/d (1,025 – 1,045 MBOE/d)
• Q4 2026 cash capital expenditures guidance of $1,000 – $1,050 million

RECENT HIGHLIGHTS

• Have repurchased 389,841 shares of common stock in Q4 2026 to date for approximately $73 million
• On October 1, redeemed all $698 million in aggregate principal amount of the Company’s 2026 Senior Notes at par
• Repurchased $195 million in aggregate principal amount of 2054 and 2064 Senior Notes at a weighted average price of 91.0% of par ($183 million, including accrued interest)

THIRD QUARTER 2026 OPERATIONS UPDATE

The following tables provide a summary of Diamondback’s key operational updates:

Wells Drilled and Completed:

Three Months Ended September 30, 2026

Nine Months Ended September 30, 2026

Drilled

Completed

Drilled

Completed

Gross

Net

Gross

Net

Gross

Net

Gross

Net

Total

105

100

135

133

320

300

450

427

Gross Wells Drilled and Completed By Zone:

		Three Months Ended September 30, 2026				Nine Months Ended September 30, 2026
		Number of Wells Drilled		Number of Wells Completed		Number of Wells Drilled		Number of Wells Completed
Midland Basin:
Upper Spraberry		3		2		6		5
Middle Spraberry		5		6		18		26
Jo Mill		17		22		55		84
Lower Spraberry		15		24		55		87
Dean		3		2		5		13
Wolfcamp A		15		36		61		105
Wolfcamp B		24		33		69		104
Wolfcamp D		9		8		27		23
Barnett		14		2		24		3
Midland Basin Total		105		135		320		450
Average Completed Lateral Length (in feet)				13,584				12,251

Realized Average Prices:

		Three Months Ended
		September 30, 2026			June 30, 2026				September 30, 2025
Oil ($ per Bbl)		$	87.30		$	96.82			$	64.60
Natural gas ($ per Mcf)		$	1.12		$	(2.15	)		$	0.75
Natural gas liquids ($ per Bbl)		$	20.02		$	18.56			$	17.28
Combined price ($ per BOE)		$	51.03		$	51.68			$	39.73
Oil, hedged ($ per Bbl)(1)		$	85.89		$	94.33			$	63.70
Natural gas, hedged ($ per Mcf)(1)		$	0.90		$	(0.34	)		$	1.75
Natural gas liquids, hedged ($ per Bbl)(1)		$	20.02		$	18.56			$	17.28
Combined price, hedged ($ per BOE)(1)		$	50.01		$	52.90			$	40.58
(1) Hedged prices reflect the effect of our commodity derivative transactions on our average sales prices and include gains and losses on cash settlements for matured commodity derivatives, which we do not designate for hedge accounting. Hedged prices exclude gains or losses resulting from the early settlement of commodity derivative contracts.

Average Cash Costs per BOE:

		Three Months Ended
		September 30, 2026			June 30, 2026			September 30, 2025
Lease operating expenses		$	5.97		$	5.96		$	5.65
Production and ad valorem taxes			3.02			3.26			2.44
Gathering, processing and transportation expense			1.32			1.22			1.41
General and administrative – cash component			0.60			0.52			0.55
Total operating expense – cash		$	10.91		$	10.96		$	10.05

FINANCIAL UPDATE

Earnings Attributable to Diamondback Energy, Inc.:

		Three Months Ended September 30, 2026
		(in millions, except per share amounts)
Net income (loss) attributable to Diamondback Energy, Inc.		$	1,603
Earnings (loss) per common share attributable to Diamondback Energy, Inc. – Diluted(1)		$	5.69
Adjusted net income(1)		$	1,649
Adjusted net income per common share – Diluted(1)		$	5.86
(1) The Company’s earnings (loss) per diluted share amount has been computed using the two-class method in accordance with GAAP. The two-class method is an earnings allocation which reflects the respective ownership among holders of common stock and participating securities. Diluted earnings per share using the two-class method is calculated as (i) net income attributable to Diamondback Energy, Inc., (ii) less the reallocation of $9 million in earnings attributable to participating securities, (iii) divided by diluted weighted average common shares outstanding for the respective periods.

Cash Capital Expenditures:

		Three Months Ended September 30,						Nine Months Ended September 30,
		2026			2025			2026			2025
		(in millions)
Operated drilling and completion additions to oil and natural gas properties		$	884		$	632		$	2,510		$	2,203
Non-operated additions to oil and natural gas properties and other			142			142			445			377
Total		$	1,026		$	774		$	2,955		$	2,580

Adjusted EBITDA and Free Cash Flow – Non-GAAP:

		Three Months Ended September 30, 2026			Nine Months Ended September 30, 2026
		(in millions)
Net income (loss) attributable to Diamondback Energy, Inc.		$	1,603		$	3,510
Consolidated Adjusted EBITDA		$	3,752		$	10,693
Adjusted EBITDA attributable to Diamondback Energy, Inc.		$	3,393		$	9,646
Net cash provided by operating activities		$	2,599		$	8,016
Free Cash Flow		$	2,148		$	6,183
Adjusted Free Cash Flow		$	2,150		$	6,218

Debt & Liquidity:

	September 30, 2026
	(in millions)
Standalone cash	$	548
Borrowings outstanding under the credit facility	$	—
Remaining availability under the credit facility	$	3,000
Total standalone liquidity	$	3,548
Consolidated total debt	$	13,375
Consolidated total net debt	$	12,817

RETURN OF CAPITAL UPDATE

Diamondback announced today that the Company’s Board of Directors (the “Board”) approved a 7.3% increase to the Company’s base cash dividend, raising it to $1.18 per common share for the third quarter of 2026, payable on November 19, 2026, to stockholders of record at the close of business on November 12, 2026.

During the third quarter, the Company repurchased 1,348,209 shares of common stock for approximately $251 million at a weighted average price of $185.94 per share (excluding excise tax). The Company expects to continue repurchases opportunistically using cash on hand, free cash flow and potential asset sale proceeds. The program has no time limit and may be suspended, modified or discontinued at the Board’s discretion. Repurchases may be executed in privately negotiated or open-market transactions, consistent with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, and will be subject to market conditions, applicable regulatory and legal requirements and other factors. All shares repurchased will be retired.

The table below summarizes Diamondback’s return of capital program, including dividends and share repurchases, with future actions subject to Board approval.

		Q32026			Q42026to date			Cumulative
		(in millions, except per share amounts, shares in thousands)
Base dividend		$	1.18
Shares repurchased			1,348			390			44,183
Weighted average repurchase price		$	185.94		$	186.69		$	143.66
Total repurchase cost		$	251		$	73		$	6,348
Total return of capital		$	582

UPDATED 2026 GUIDANCE

Below is Diamondback’s and Viper Energy, Inc.’s (“Viper”) updated guidance for the full year 2026, which includes fourth quarter production and capital guidance.

	2026 Guidance	2026 Guidance
	Diamondback Energy, Inc.	Viper Energy, Inc.
2026 Net production – MBOE/d	~1,015 (from 1,000+)	137.0 – 138.0
2026 Oil production – MBO/d	~524 (from 522+)	67.25 – 67.75
Q4 2026 Oil production – MBO/d (total – MBOE/d)	518 – 528 (1,025 – 1,045)	70.0 – 71.0 (141.5 – 143.5)
Unit costs ($/BOE)
Lease operating expenses, including workovers	$5.95 – $6.20 (from $5.90 – $6.40)
G&A
Cash G&A	$0.55 – $0.65	$0.70 – $0.90
Non-cash equity-based compensation	$0.20 – $0.30	$0.10 – $0.20
DD&A	$13.50 – $14.50	$14.75 – $17.25
Interest expense (net of interest income)	$0.50 – $0.70	$1.90 – $2.40
Gathering, processing and transportation	$1.30 – $1.50 (from $1.40 – $1.60)
Production and ad valorem taxes (% of revenue)	~6.5% (from ~7%)	~7%
Corporate tax rate (% of pre-tax income)	23%
Cash tax rate (% of pre-tax income)(1)	19% – 22%	27% – 30%
Q4 2026 Cash taxes ($ – million)	$500 – $560
Cash Capital Budget ($ – million)
Operated drilling and completion	$3,350 – $3,400 (from ~$3,310)
2026 Total capital expenditures(2)	$3,950 – $4,000 (from ~$3,900)
Q4 2026 Capital expenditures	$1,000 – $1,050
Average lateral length (Ft.)	~12,900′
Net lateral footage completed (1,000’s of Ft.)	6,200′ – 6,600′ (from 6,100′ – 6,500′)
(1) Pre-tax income attributable to the Company is a non-GAAP measure. We are not able to forecast the most directly comparable GAAP measure – Income (loss) before income taxes – due to high variability and difficulty in predicting certain items that affect Income (loss) before income taxes, such as future commodity prices, pace of and costs of developing, producing and operating our interests in oil and natural gas properties, future changes in interest rates and various other business factors impacting our financial results. (2) Includes non-operated drilling and completion, capital workovers, science, infrastructure, midstream and environmental.

CONFERENCE CALL

Diamondback will host a conference call and webcast for investors and analysts to discuss its results for the third quarter of 2026 on Tuesday, November 3, 2026 at 8:00 a.m. CT. Access to the webcast, and replay which will be available following the call, may be found here. The live webcast of the earnings conference call will also be available via Diamondback’s website at www.diamondbackenergy.com under the “Investor Relations” section of the site. Investors and others should note that Diamondback announces material financial and operational information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The information we post through our investor relations website may be deemed material. Accordingly, investors should monitor our investor relations website in addition to following our press releases, SEC filings and public conference calls and webcasts.

About Diamondback Energy, Inc.

Diamondback is an independent oil and natural gas company headquartered in Midland, Texas focused on the acquisition, development, exploration and exploitation of unconventional, onshore oil and natural gas reserves primarily in the Permian Basin in West Texas. For more information, please visit www.diamondbackenergy.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, including statements regarding Diamondback’s: future performance; business strategy; future operations (including drilling plans and capital plans); estimates and projections of revenues, losses, costs, expenses, returns, cash flow, and financial position; reserve estimates and its ability to replace or increase reserves; anticipated benefits or other effects of strategic transactions (including the 2026 Drop Down, the Viper Riverbend acquisition, the Viper McElroy Ranch acquisition and Viper’s Sitio acquisition and other acquisitions, divestitures or reorganizations); and plans and objectives of management (including plans for future cash flow from operations and for executing environmental strategies) are forward-looking statements. When used in this news release, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Diamondback believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond Diamondback’s control. Accordingly, forward-looking statements are not guarantees of future performance and Diamondback’s actual outcomes could differ materially from what Diamondback has expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: geopolitics and market conditions, including changes in supply and demand levels for oil, natural gas, and natural gas liquids, and the resulting impact on the price for those commodities; changes in U.S. energy, environmental, monetary and trade policies, including with respect to tariffs or other trade barriers and any resulting trade tensions; actions taken by the members of OPEC and its non-OPEC allies (OPEC+) affecting the production and pricing of oil, as well as other domestic and global political, economic, or diplomatic developments; changes in general economic, business or industry conditions, including changes in foreign currency exchange rates, interest rates, inflation rates, and instability in the financial markets; regional supply and demand factors, including delays, curtailments or interruptions of production, or governmental orders, rules or regulations that impose production limits; federal and state legislative and regulatory initiatives relating to hydraulic fracturing, including the effect of existing and future laws and governmental regulations; physical and transition risks relating to climate change, changing political and social perspectives on climate change and other environmental, social and governance factors, and risks from our publicly disclosed targets related to sustainability and emissions reduction initiatives; challenges in developing our existing leasehold acreage and finding, developing or acquiring additional reserves; restrictions on the use of water, including limits on the use of produced water and a moratorium on new produced water disposal well permits recently imposed by the Texas Railroad Commission in an effort to control induced seismicity in the Permian Basin; significant declines in prices for oil, natural gas, or natural gas liquids, which could require recognition of significant impairment charges; conditions in the capital, financial and credit markets, including the availability and pricing of capital for acquisitions, exploration and development operations; challenges with employee retention and an increasingly competitive labor market; changes in availability or cost of rigs, equipment, raw materials, supplies and oilfield services; changes in safety, health, environmental, tax and other regulations or requirements (including those addressing air emissions, water management, or the impact of global climate change); security threats, including cybersecurity threats and disruptions to our business and operations from breaches of our information technology systems, or from breaches of information technology systems of third parties with whom we transact business; lack of, or disruption in, access to adequate and reliable electrical power, internet and telecommunication infrastructure, information and computer systems, transportation, processing, storage and other facilities for our oil, natural gas and natural gas liquids; failures or delays in achieving expected reserve or production levels from existing and future oil and natural gas developments, including due to operating hazards, drilling risks, or the inherent uncertainties in predicting reserve and reservoir performance; inability to keep pace with technological developments in our industry; failure to meet our obligations under our oil purchase contracts; loss of one or more customers or their inability to meet their obligations; geographical concentration of our primary operations; risks from our return of capital activity, and uncertainties over our future dividends and share repurchases; difficulty in obtaining necessary approvals and permits; severe weather conditions and natural disasters; changes in the financial strength of counterparties to our credit facilities and hedging contracts; our substantial indebtedness and restrictions to our operating and financial flexibility; changes in our credit rating; failure to identify, complete and successfully integrate acquisitions, including Viper’s Riverbend acquisition, Viper’s McElroy Ranch acquisition and Viper’s Sitio acquisition; the Endeavor stockholders’ ability to significantly influence our business and potential conflicts of interest; and other risks described in Part I, Item 1A of Diamondback’s Annual Report on Form 10-K, filed with the SEC on February 25, 2026, and those risks disclosed in its subsequent filings on Forms 10-K, 10-Q and 8-K, which can be obtained free of charge on the SEC’s website at http://www.sec.gov and Diamondback’s website at www.diamondbackenergy.com/investors.

In light of these factors, the events anticipated by Diamondback’s forward-looking statements may not occur at the time anticipated or at all. Moreover, Diamondback operates in a very competitive and rapidly changing environment and new risks emerge from time to time. Diamondback cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements. All forward-looking statements speak only as of the date of this release or, if earlier, as of the date they were made. Diamondback does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

Diamondback Energy, Inc.
Condensed Consolidated Statements of Operations
(unaudited, in millions, except per share amounts, shares in thousands)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Revenues:
Oil, natural gas and natural gas liquid sales		$	4,854			$	3,447			$	13,465			$	10,420
Sales of purchased oil			536				459				1,660				1,168
Other operating income			41				18				108				62
Total revenues			5,431				3,924				15,233				11,650
Costs and expenses:
Lease operating expenses			568				490				1,667				1,338
Production and ad valorem taxes			287				212				857				654
Gathering, processing and transportation			126				122				359				378
Purchased oil expense			540				455				1,663				1,168
Depreciation, depletion, amortization and accretion			1,320				1,286				3,885				3,649
Impairment of oil and natural gas properties			—				—				1,400				—
General and administrative expenses			83				70				234				210
Other operating expenses, net			7				53				40				205
Total costs and expenses			2,931				2,688				10,105				7,602
Income (loss) from operations			2,500				1,236				5,128				4,048
Other income (expense):
Interest expense, net			(55	)			(70	)			(174	)			(166	)
Other income (expense), net			5				116				8				153
Gain (loss) on derivative instruments, net			(182	)			120				(16	)			149
Gain (loss) on extinguishment of debt, net			4				(32	)			137				23
Total other income (expense), net			(228	)			134				(45	)			159
Income (loss) before income taxes			2,272				1,370				5,083				4,207
Provision for (benefit from) income taxes			501				287				1,113				894
Net income (loss)			1,771				1,083				3,970				3,313
Net income (loss) attributable to non-controlling interest			168				65				460				191
Net income (loss) attributable to Diamondback Energy, Inc.		$	1,603			$	1,018			$	3,510			$	3,122
Earnings (loss) per common share:
Basic		$	5.69			$	3.51			$	12.41			$	10.71
Diluted		$	5.69			$	3.51			$	12.41			$	10.71
Weighted average common shares outstanding:
Basic			279,959				288,826				281,307				290,188
Diluted			279,959				288,826				281,307				290,188

Diamondback Energy, Inc.
Condensed Consolidated Balance Sheets
(unaudited, in millions, except share amounts)
		September 30,				December 31,
			2026				2025
Assets
Current assets:
Cash and cash equivalents ($10 million and $13 million related to Viper)		$	558			$	104
Restricted cash			2				2
Accounts receivable:
Joint interest and other, net			247				258
Oil and natural gas sales, net ($496 million and $262 million related to Viper)			2,118				1,128
Inventories			64				86
Prepaid expenses and other current assets			158				337
Total current assets			3,147				1,915
Property and equipment:
Oil and natural gas properties:
Proved properties ($10,102 million and $9,746 million related to Viper)			77,090				71,588
Unproved properties ($5,213 million and $4,910 million related to Viper)			22,990				23,941
Other property, equipment and land			932				874
Accumulated depletion, depreciation, amortization and impairment ($3,062 million and $2,455 million related to Viper)			(33,000	)			(27,782	)
Property and equipment, net			68,012				68,621
Other assets			951				523
Total assets		$	72,110			$	71,059
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued capital expenditures			1,374				1,168
Current maturities of debt			1,548				763
Other accrued liabilities			1,033				1,108
Revenues and royalties payable			1,645				1,397
Derivative instruments			47				15
Income taxes payable			92				149
Total current liabilities			5,739				4,600
Long-term debt ($2,394 million and $2,186 million related to Viper)			11,682				13,726
Deferred income taxes			8,936				9,141
Other long-term liabilities			620				625
Total liabilities			26,977				28,092
Stockholders’ equity:
Common stock, $0.01 par value; 800,000,000 shares authorized; 279,241,756 and 284,594,908 shares issued and outstanding at September 30, 2026, and December 31, 2025, respectively			3				3
Additional paid-in capital			31,638				32,236
Retained earnings (accumulated deficit)			7,332				4,740
Accumulated other comprehensive income (loss)			(7	)			(7	)
Total Diamondback Energy, Inc. stockholders’ equity			38,966				36,972
Non-controlling interest			6,167				5,995
Total equity			45,133				42,967
Total liabilities and stockholders’ equity		$	72,110			$	71,059

Diamondback Energy, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited, in millions)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Cash flows from operating activities:
Net income (loss)		$	1,771			$	1,083			$	3,970			$	3,313
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Provision for (benefit from) deferred income taxes			(7	)			253				(213	)			235
Depreciation, depletion, amortization and accretion			1,320				1,286				3,885				3,649
Impairment of oil and natural gas properties			—				—				1,400				—
(Gain) loss on extinguishment of debt, net			(4	)			32				(137	)			(23	)
(Gain) loss on derivative instruments, net			182				(120	)			16				(149	)
Cash received (paid) on settlement of derivative instruments			(97	)			60				149				108
Other			9				(60	)			68				(6	)
Changes in operating assets and liabilities:
Accounts receivable			(476	)			(22	)			(1,039	)			138
Accounts payable and accrued liabilities			71				28				(133	)			(355	)
Income taxes payable			(138	)			(206	)			(138	)			(515	)
Revenues and royalties payable			(54	)			58				270				28
Other			22				(9	)			(82	)			(8	)
Net cash provided by (used in) operating activities			2,599				2,383				8,016				6,415
Cash flows from investing activities:
Additions to oil and natural gas properties			(1,026	)			(774	)			(2,955	)			(2,580	)
Property acquisitions			(1,157	)			(1,536	)			(1,909	)			(5,411	)
Proceeds from sale of assets			66				257				723				314
Other			(193	)			(6	)			(222	)			(14	)
Net cash provided by (used in) investing activities			(2,310	)			(2,059	)			(4,363	)			(7,691	)
Cash flows from financing activities:
Proceeds from debt			3,115				4,400				9,405				13,022
Repayment of debt			(2,500	)			(3,313	)			(10,547	)			(9,720	)
Repurchased shares under repurchase program			(251	)			(603	)			(431	)			(1,576	)
Repurchased shares – related party			—				—				(509	)			—
Repurchased shares/units under Viper’s repurchase program			(90	)			(90	)			(318	)			(100	)
Net proceeds from Viper’s issuance of common stock			—				—				—				1,232
Proceeds from sale of Viper’s common stock			—				—				589				—
Payments for dividends and dividend equivalents			(309	)			(290	)			(918	)			(874	)
Dividends to non-controlling interest			(158	)			(79	)			(437	)			(256	)
Other			—				(18	)			(33	)			(64	)
Net cash provided by (used in) financing activities			(193	)			7				(3,199	)			1,664
Net increase (decrease) in cash, cash equivalents and restricted cash			96				331				454				388
Cash, cash equivalents and restricted cash at beginning of period			464				221				106				164
Cash, cash equivalents and restricted cash at end of period		$	560			$	552			$	560			$	552

Diamondback Energy, Inc.
Selected Operating Data
(unaudited)
		Three Months Ended
		September 30, 2026				June 30, 2026				September 30, 2025
Production Data:
Oil (MBbls)			48,295				47,791				46,345
Natural gas (MMcf)			135,002				128,279				115,353
Natural gas liquids (MBbls)			24,330				23,436				21,180
Combined volumes (MBOE)(1)			95,125				92,607				86,751
Daily oil volumes (BO/d)			524,946				525,176				503,750
Daily combined volumes (BOE/d)			1,033,967				1,017,659				942,946
Average Prices:
Oil ($ per Bbl)		$	87.30			$	96.82			$	64.60
Natural gas ($ per Mcf)		$	1.12			$	(2.15	)		$	0.75
Natural gas liquids ($ per Bbl)		$	20.02			$	18.56			$	17.28
Combined price ($ per BOE)		$	51.03			$	51.68			$	39.73
Oil, hedged ($ per Bbl)(2)		$	85.89			$	94.33			$	63.70
Natural gas, hedged ($ per Mcf)(2)		$	0.90			$	(0.34	)		$	1.75
Natural gas liquids, hedged ($ per Bbl)(2)		$	20.02			$	18.56			$	17.28
Combined price, hedged ($ per BOE)(2)		$	50.01			$	52.90			$	40.58
Average Cash Costs ($/BOE):
Lease operating expenses		$	5.97			$	5.96			$	5.65
Production and ad valorem taxes			3.02				3.26				2.44
Gathering, processing and transportation expense			1.32				1.22				1.41
General and administrative – cash component			0.60				0.52				0.55
Total operating expense – cash		$	10.91			$	10.96			$	10.05
General and administrative – non-cash component		$	0.27			$	0.26			$	0.25
Depreciation, depletion, amortization and accretion		$	13.88			$	13.74			$	14.82
Interest expense, net		$	0.58			$	0.60			$	0.81
(1) Bbl equivalents are calculated using a conversion rate of six Mcf per one Bbl. (2) Hedged prices reflect the effect of our commodity derivative transactions on our average sales prices and include gains and losses on cash settlements for matured commodity derivatives, which we do not designate for hedge accounting. Hedged prices exclude gains or losses resulting from the early settlement of commodity derivative contracts.

NON-GAAP FINANCIAL MEASURES

ADJUSTED EBITDA

Adjusted EBITDA is a supplemental non-GAAP financial measure that is used by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. The Company defines Adjusted EBITDA as net income (loss) attributable to Diamondback Energy, Inc., plus net income (loss) attributable to non-controlling interest (“net income (loss)”) before non-cash (gain) loss on derivative instruments, net, interest expense, net, depreciation, depletion, amortization and accretion, depreciation and interest expense related to equity method investments, (gain) loss on extinguishment of debt, impairment of oil and natural gas properties, non-cash equity-based compensation expense, capitalized equity-based compensation expense, other non-cash transactions and provision for (benefit from) income taxes. Adjusted EBITDA is not a measure of net income as determined by United States generally accepted accounting principles (“GAAP”). Management believes Adjusted EBITDA is useful because the measure allows it to evaluate the Company’s operating performance and compare the results of its operations from period to period without regard to its financing methods or capital structure. The Company excludes the items listed above from net income (loss) to determine Adjusted EBITDA because these amounts can vary substantially from company to company within its industry depending upon accounting methods and book values of assets, capital structures and the method by which the assets were acquired. Further, the Company excludes the effects of significant transactions that may affect earnings but are unpredictable in nature, timing and amount, although they may recur in different reporting periods. Adjusted EBITDA should not be considered as an alternative to, or more meaningful than, net income as determined in accordance with GAAP or as an indicator of the Company’s operating performance. Certain items excluded from Adjusted EBITDA are significant components in understanding and assessing a company’s financial performance, such as a company’s cost of capital and tax structure, as well as the historic costs of depreciable assets. The Company’s computation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies or to such measure in our credit facility or any of our other contracts.

The following tables present a reconciliation of the GAAP financial measure of net income (loss) attributable to Diamondback Energy, Inc. to the non-GAAP financial measure of Adjusted EBITDA:

Diamondback Energy, Inc.
Reconciliation of Net Income (Loss) to Adjusted EBITDA
(unaudited, in millions)
		Three Months Ended September 30, 2026				Nine Months Ended September 30, 2026
Net income (loss) attributable to Diamondback Energy, Inc.		$	1,603			$	3,510
Net income (loss) attributable to non-controlling interest			168				460
Net income (loss)			1,771				3,970
Non-cash (gain) loss on derivative instruments, net			85				165
Interest expense, net			55				174
Depreciation, depletion, amortization and accretion			1,320				3,885
Depreciation and interest expense related to equity method investments			13				39
(Gain) loss on extinguishment of debt			(4	)			(137	)
Impairment of oil and natural gas properties			—				1,400
Non-cash equity-based compensation expense			37				101
Capitalized equity-based compensation expense			(11	)			(29	)
Other non-cash transactions			(15	)			12
Provision for (benefit from) income taxes			501				1,113
Consolidated Adjusted EBITDA			3,752				10,693
Less: Adjustment for non-controlling interest			359				1,047
Adjusted EBITDA attributable to Diamondback Energy, Inc.		$	3,393			$	9,646

ADJUSTED NET INCOME

Adjusted net income is a non-GAAP financial measure equal to net income (loss) attributable to Diamondback Energy, Inc. plus net income (loss) attributable to non-controlling interest (“net income (loss)”) adjusted for non-cash (gain) loss on derivative instruments, net, (gain) loss on extinguishment of debt, other non-cash transactions and related income tax adjustments. The Company’s computation of adjusted net income may not be comparable to other similarly titled measures of other companies or to such measure in our credit facility or any of our other contracts. Management believes adjusted net income helps investors in the oil and natural gas industry to measure and compare the Company’s performance to other oil and natural gas companies by excluding from the calculation items that can vary significantly from company to company depending upon accounting methods, the book value of assets and other non-operational factors. Further, in order to allow investors to compare the Company’s performance across periods, the Company excludes the effects of significant transactions that may affect earnings but are unpredictable in nature, timing and amount, although they may recur in different reporting periods.

The following table presents a reconciliation of the GAAP financial measure of net income (loss) attributable to Diamondback Energy, Inc. to the non-GAAP measure of adjusted net income:

Diamondback Energy, Inc.
Adjusted Net Income
(unaudited, in millions, except per share amounts, shares in thousands)
		Three Months Ended
		September 30, 2026
		Amounts				Amounts Per Diluted Share
Net income (loss) attributable to Diamondback Energy, Inc.(1)		$	1,603			$	5.69
Net income (loss) attributable to non-controlling interest			168				0.60
Net income (loss)(1)			1,771				6.29
Non-cash (gain) loss on derivative instruments, net			85				0.30
(Gain) loss on extinguishment of debt			(4	)			(0.01	)
Other non-cash transactions			(15	)			(0.05	)
Adjusted net income excluding above items(1)			1,837				6.53
Income tax adjustment for above items			(15	)			(0.05	)
Adjusted net income(1)			1,822				6.48
Less: Adjusted net income attributable to non-controlling interest			173				0.62
Adjusted net income attributable to Diamondback Energy, Inc.(1)		$	1,649			$	5.86
Weighted average common shares outstanding:
Basic							279,959
Diluted							279,959
(1) The Company’s earnings (loss) per diluted share amount has been computed using the two-class method in accordance with GAAP. The two-class method is an earnings allocation which reflects the respective ownership among holders of common stock and participating securities. Diluted earnings per share using the two-class method is calculated as (i) net income attributable to Diamondback Energy, Inc., (ii) less the reallocation of $9 million in earnings attributable to participating securities, (iii) divided by diluted weighted average common shares outstanding for the respective periods.

OPERATING CASH FLOW BEFORE WORKING CAPITAL CHANGES, FREE CASH FLOW AND ADJUSTED FREE CASH FLOW

Operating cash flow before working capital changes, which is a non-GAAP financial measure, represents net cash provided by operating activities as determined under GAAP without regard to changes in working capital. The Company believes operating cash flow before working capital changes is a useful measure of an oil and natural gas company’s ability to generate cash used to fund exploration, development and acquisition activities and service debt or pay dividends. The Company also uses this measure because changes in working capital relate to the timing of cash receipts and disbursements that the Company may not control and may not relate to the period in which the operating activities occurred. This allows the Company to compare its operating performance with that of other companies without regard to financing methods and capital structure.

The Company defines Free Cash Flow, which is a non-GAAP financial measure, as cash flow from operating activities before changes in working capital in excess of cash capital expenditures. The Company defines Adjusted Free Cash Flow, which is a non-GAAP financial measure, as Free Cash Flow before the tax impact from divestitures (if any), merger and transaction expenses, costs of early termination of derivatives and settlements of any treasury locks (if any). The Company believes that Free Cash Flow and Adjusted Free Cash Flow are useful to investors as they provide a measure to compare both cash flow from operating activities and additions to oil and natural gas properties across periods on a consistent basis, adjusted, as applicable, for non-recurring impacts from divestitures, merger and transaction expenses, the early termination of derivative contracts and settlements of treasury locks. These measures should not be considered as an alternative to, or more meaningful than, net cash provided by operating activities as an indicator of liquidity. The Company’s computation of Free Cash Flow may not be comparable to other similarly titled measures of other companies.

The following tables present a reconciliation of the GAAP financial measure of net cash provided by operating activities to the non-GAAP measure of operating cash flow before working capital changes and to the non-GAAP measures of Free Cash Flow and Adjusted Free Cash Flow:

Diamondback Energy, Inc.
Operating Cash Flow Before Working Capital Changes, Free Cash Flow and Adjusted Free Cash Flow
(unaudited, in millions)
		Three Months Ended September 30, 2026				Nine Months Ended September 30, 2026
Net cash provided by operating activities		$	2,599			$	8,016
Less: Changes in cash due to changes in operating assets and liabilities:
Accounts receivable			(476	)			(1,039	)
Accounts payable and accrued liabilities			71				(133	)
Income taxes payable			(138	)			(138	)
Revenues and royalties payable			(54	)			270
Other			22				(82	)
Total working capital changes			(575	)			(1,122	)
Operating cash flow before working capital changes			3,174				9,138
Additions to oil and natural gas properties			(1,026	)			(2,955	)
Total Cash CAPEX			(1,026	)			(2,955	)
Free Cash Flow			2,148				6,183
Merger and transaction expenses(1)			2				8
Early termination of derivatives			—				27
Adjusted Free Cash Flow		$	2,150			$	6,218
(1) Includes $4 million of Viper’s transaction expenses primarily related to the Sitio Acquisition for the nine months ended September 30, 2026.

NET DEBT

The Company defines the non-GAAP measure of net debt as total debt (excluding debt issuance costs, discounts, premiums and unamortized basis adjustments) less cash and cash equivalents and restricted cash that has been irrevocably deposited for the redemption of principal amounts of outstanding senior notes. Net debt should not be considered an alternative to, or more meaningful than, total debt, the most directly comparable GAAP measure. Management uses net debt to determine the Company’s outstanding debt obligations that would not be readily satisfied by its cash and cash equivalents on hand. The Company believes this metric is useful to analysts and investors in determining the Company’s leverage position because the Company has the ability to, and may decide to, use a portion of its cash and cash equivalents to reduce debt.

Diamondback Energy, Inc.
Net Debt
(unaudited, in millions)
		September 30, 2026				Net Q3 Principal Borrowings/ (Repayments)				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025
Diamondback total debt(1)		$	10,965			$	(106	)		$	11,071			$	12,448			$	12,462			$	13,792
Diamondback cash and cash equivalents			(548	)							(385	)			(146	)			(91	)			(106	)
Diamondback net debt		$	10,417							$	10,686			$	12,302			$	12,371			$	13,686
Viper total debt(1)		$	2,410			$	715			$	1,695			$	1,620			$	2,205			$	2,640
Viper cash and cash equivalents			(10	)							(77	)			(28	)			(13	)			(433	)
Viper net debt		$	2,400							$	1,618			$	1,592			$	2,192			$	2,207
Total debt		$	13,375			$	609			$	12,766			$	14,068			$	14,667			$	16,432
Cash and cash equivalents			(558	)							(462	)			(174	)			(104	)			(539	)
Net debt		$	12,817							$	12,304			$	13,894			$	14,563			$	15,893
(1) Excludes debt issuance costs, discounts, premiums and unamortized basis adjustments.

DERIVATIVES

As of October 30, 2026, the Company had the following outstanding consolidated derivative contracts, including derivative contracts at Viper. The Company’s derivative contracts are based upon reported settlement prices on commodity exchanges and published index prices. Crude oil derivative settlements are based on New York Mercantile Exchange (“NYMEX”) West Texas Intermediate (“WTI”) pricing, Crude Oil Brent pricing and the regional crude oil pricing points indicated below. Natural gas derivative settlements are based on NYMEX Henry Hub pricing and the regional natural gas pricing points indicated below. Basis swaps settle on the differential between the applicable benchmark price and the regional index price, and roll swaps settle on the differential between NYMEX WTI prompt-month and second-month contract prices. When aggregating multiple contracts, the weighted average contract price is disclosed.

		Crude Oil (Bbls/day, $/Bbl)
		Q4 2026			Q1 2027			Q2 2027			Q3 2027			Q4 2027
Long Puts – Crude Brent Oil			10,000			15,000			10,000			—			—
Long Put Price ($/Bbl)		$	55.00		$	55.00		$	55.00			—			—
Deferred Premium ($/Bbl)		$	-1.33		$	-1.27		$	-1.21			—			—
Long Puts – WTI (Magellan East Houston)			75,000			75,000			60,000			30,000			10,000
Long Put Price ($/Bbl)		$	50.67		$	50.00		$	50.00		$	50.00		$	50.00
Deferred Premium ($/Bbl)		$	-1.31		$	-1.25		$	-1.25		$	-1.15		$	-0.98
Long Puts – WTI (Cushing)			175,000			140,000			130,000			90,000			40,000
Long Put Price ($/Bbl)		$	50.57		$	50.00		$	50.00		$	50.00		$	50.00
Deferred Premium ($/Bbl)		$	-1.28		$	-1.28		$	-1.24		$	-1.22		$	-1.15
Basis Swaps – WTI (Midland)			85,000			41,500			41,500			31,500			31,500
		$	1.09		$	1.30		$	1.30		$	1.07		$	1.07
WTI / Brent Basis Puts			290,000			—			—			—			—
Spread ($/Bbl)		$	-41.03			—			—			—			—
Deferred Premium ($/Bbl)		$	-1.44			—			—			—			—
Roll Swaps – WTI			150,000			—			—			—			—
		$	2.89			—			—			—			—

		Natural Gas (Mmbtu/day, $/Mmbtu)
		Q4 2026			FY 2027			FY 2028
Costless Collars – Henry Hub			840,000			720,000			130,000
Floor Price ($/Mmbtu)		$	2.87		$	2.88		$	2.65
Ceiling Price ($/Mmbtu)		$	6.35		$	6.37		$	5.88
Natural Gas Basis Swaps – Waha Hub			650,000			370,000			60,000
		$	-1.75		$	-1.27		$	-1.51
Natural Gas Basis Swaps – Houston Ship Channel			100,000			300,000			150,000
		$	-0.35		$	-0.31		$	-0.33

Investor Contact:
Adam Lawlis
+1 432.221.7467
alawlis@diamondbackenergy.com

MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the following investor conferences:

• Canaccord Genuity Medtech, Diagnostics & Digital Health Services Forum in New York on Wednesday, Nov. 11, 2026. The fireside chat is scheduled at 8:00 a.m. (ET) the same day via webcast.
• Jefferies Global Healthcare Conference in London on Thursday, Nov. 19, 2026. The Company’s presentation will begin at 1:00 p.m. (GMT) / 9:00 a.m. (ET) the same day via webcast.

A live webcast of the events can be found at ir.cvrx.com. An archived version of the presentation will be available following the live events and can be accessed at the same location for a limited time.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in five investor conferences.

• Guggenheim 3rd Annual Healthcare Innovation Conference: Marino Garcia, CEO, will participate in a fireside chat on Monday, November 9, 2026, at 11:00 a.m. ET. Marino Garcia and Ryan Savitz, EVP, CFO & CBO, will also host one-on-one investor meetings.
• Stifel 2026 Healthcare Conference: Marino Garcia will participate in a fireside chat on Wednesday, November 11, 2026, at 9:20 a.m. ET. Marino Garcia and Ryan Savitz will also host one-on-one investor meetings.
• 2026 Truist Securities BioPharma Symposium: Ryan Savitz will host one-on-one investor meetings on Thursday, November 12, 2026.
• UBS Global Biopharma Conference: Marino Garcia will participate in a fireside chat on Monday, November 16, 2026, at 9:20 a.m. GMT. Marino Garcia and Ryan Savitz will also host one-on-one investor meetings.
• Jefferies Global Healthcare Conference: Marino Garcia will participate in a fireside chat on Wednesday, November 18, 2026, at 2:30 p.m. GMT. Marino Garcia and Ryan Savitz will also host one-on-one investor meetings.

Webcasts of the fireside chats may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026.

Company Presentation Details:

Date:	Monday, November 9, 2026
Time:	4:30pm EST (2:30pm PCT)
Webcast:	Pre-register here
Dial-In:	(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:	8984105

A live webcast of the company presentation will be available on the Investors section of Xenon’s website and posted for replay following the event. The above-mentioned dates and times are subject to change.

About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K_V7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_V7 and Na_V1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner.

Contacts: 
For Investors:
Laura Perry/Emily Huang
Argot Partners
Xenon@argotpartners.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com

DALLAS, Nov. 02, 2026 (GLOBE NEWSWIRE) — Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced its financial results for the second fiscal quarter ended September 30, 2026.

Second Quarter Fiscal Year 2027 Financial Highlights

• Total Investment Portfolio at Fair Value: $2.4 billion
  • Credit Portfolio at Fair Value of $2.2 billion
    • 99% 1st Lien Senior Secured Debt
    • $376.8 million in new committed credit investments during the quarter
    • Weighted Average Yield on Debt Investments: 10.9%
    • Current non-accruals with a fair value of $34.8 million, representing 1.4% of the total investment portfolio, and a cost basis of $85.5 million, representing 3.5% of the total investment portfolio
  • Equity Portfolio at Fair Value of $192.3 million, excluding investment in CapTrin Partners, LLC (“CapTrin”) and Desert Star 2026 LLC (“Desert Star”), CSWC’s unconsolidated joint ventures (“JV equity”)
    • $14.2 million in new equity co-investments during the quarter
  • CSWC Joint Venture (“JV”) Equity Investments at Fair Value: $36.4 million
    • Investment in CapTrin at fair value of $28.4 million
      • CapTrin portfolio at fair value of $126.7 million
    • Investment in Desert Star at fair value of $7.9 million
      • $25.0 million in new commitment to Desert Star during the quarter
      • Desert Star portfolio at fair value of $128.2 million
• Pre-Tax Net Investment Income: $37.2 million, or $0.58 per weighted average common share outstanding
• Estimated Undistributed Taxable Income (“UTI”): $0.92 per share as of September 30, 2026
• LTM Operating Leverage: 1.4% as of September 30, 2026
• Dividends: Paid Total Dividends for the quarter ended September 30, 2026 of $0.64
  • Paid $0.58 per share Regular Quarterly Dividend ($0.1934 per share in each of July, August and September 2026)
  • Paid $0.06 per share Supplemental Quarterly Dividend in September 2026
• Net Realized and Unrealized Depreciation: $13.4 million, or 0.6% of total investments at fair value
  • $1.7 million of net appreciation related to the equity portfolio
  • $14.6 million of net depreciation related to the credit portfolio
  • $0.5 million net realized and unrealized income tax provision
• Balance Sheet:
  • Cash and Cash Equivalents: $48.0 million
  • Total Net Assets: $1.1 billion
  • Net Asset Value (“NAV”) per Share: $16.64

In commenting on the Company’s results, Michael Sarner, President and Chief Executive Officer, stated, “Capital Southwest delivered the largest origination quarter in our history, with approximately $391 million of originations across 14 new and 16 existing portfolio companies. We also committed $25 million to Desert Star, a new joint venture with Trinity Capital. This new joint venture gives us access to the technology lending market in partnership with Trinity, allowing us to gain exposure through a granular portfolio of investments in an area where we have not historically focused.

Our portfolio continued to generate strong earnings for our shareholders, producing $0.58 of pre-tax net investment income per share. Reflecting the strength of our earnings profile, the Board of Directors again declared a regular quarterly dividend of $0.58 per share, of which $0.1934 per share will be paid for each of October, November and December 2026, and a supplemental quarterly dividend of $0.06 to be paid in December 2026.

We also continued to strengthen and diversify our capital base. During the quarter, we successfully raised a new $350 million unsecured bond at 6.75%, which we used to pay down our Corporate Credit Facility. We also continued to efficiently raise equity capital during the quarter, raising approximately $67 million through our Equity ATM Program. Finally, pursuant to recent legislation, we received SBA approval to increase Capital Southwest SBIC II, LP’s leverage commitment from $175 million to $250 million, further enhancing our capacity to deploy capital through SBIC II.”

Second Quarter Fiscal Year Investment Activities

During the quarter ended September 30, 2026, the Company originated $391.0 million in new commitments, consisting of investments in 14 new portfolio companies totaling $327.1 million and add-on commitments in 16 portfolio companies totaling $63.9 million. New portfolio company originations were comprised of $314.2 million in first lien senior secured debt and $12.9 million in equity investments. The Company also committed $25.0 million in equity to Desert Star.

During the quarter ended September 30, 2026, the Company received proceeds of $74.2 million from four portfolio company prepayments and exits, generating a weighted average IRR of 14.5%. Total proceeds were comprised of $69.1 million from debt investments and $5.1 million from equity investments.

Second Fiscal Quarter 2027 Operating Results

For the quarter ended September 30, 2026, Capital Southwest reported total investment income of $67.2 million, compared to $61.0 million in the prior quarter. The increase in investment income was primarily attributable to an increase in interest income due to an increase in the weighted average cost basis of investments held.

For the quarter ended September 30, 2026, total operating expenses (excluding interest expense) were $9.0 million, compared to $7.6 million in the prior quarter. The increase was primarily attributable to an increase in legal fees and proxy solicitation expenses incurred in connection with our annual meeting of shareholders, as well as an increase in employee compensation.

For the quarter ended September 30, 2026, interest expense was $21.0 million, compared to $18.5 million in the prior quarter. The increase is primarily attributable to an increase in average borrowings outstanding and an increase in the weighted average interest rate on total debt.

For the quarter ended September 30, 2026, total pre-tax net investment income was $37.2 million, compared to $35.0 million in the prior quarter.

For the quarter ended September 30, 2026, there was a tax provision of $0.9 million, compared to a tax benefit of $0.7 million in the prior quarter. The change was primarily driven by deferred tax adjustments related to the tax basis of investments held at Capital Southwest Equity Investments, Inc., our wholly owned subsidiary that has elected to be treated as a corporation for U.S. federal income tax purposes.

During the quarter ended September 30, 2026, Capital Southwest recorded total net realized and unrealized losses on investments of $13.4 million, compared to $10.9 million of total net realized and unrealized losses in the prior quarter. For the quarter ended September 30, 2026, the total net realized and unrealized losses on investments reflected net realized and unrealized appreciation on equity investments of $1.7 million, net realized and unrealized depreciation on debt investments of $14.6 million, and a net realized and unrealized income tax provision of $0.5 million. The net increase in net assets resulting from operations was $21.4 million for the quarter, compared to $24.7 million in the prior quarter.

The Company’s NAV at September 30, 2026 was $16.64 per share, compared to $16.61 per share in the prior quarter. The increase in NAV per share from the prior quarter is primarily due to the issuance of common stock at a premium to NAV per share through the Equity ATM Program (as described below), partially offset by net realized and unrealized losses on investments.

Liquidity and Capital Resources

At September 30, 2026, Capital Southwest had approximately $48.0 million in unrestricted cash and money market balances and $599.2 million of unused capacity under the Corporate Credit Facility (as defined below) and the SPV Credit Facility (as defined below). The regulatory debt to equity ratio at the end of the quarter was 1.00 to 1.

As of September 30, 2026, Capital Southwest had the following borrowings outstanding:

• $90.0 million of total debt outstanding on the Corporate Credit Facility
• $105.0 million of total debt outstanding on the SPV Credit Facility
• $225.3 million, net of amortized debt issuance costs, of the 5.125% convertible notes due November 2029
• $344.6 million, net of amortized debt issuance costs, of the 5.950% Notes due 2030
• $337.9 million, net of amortized debt issuance costs and effective hedge accounting adjustment, of the 6.750% Notes due 2031
• $281.7 million, net of unamortized debt issuance costs, of SBA Debentures (as defined below)

In August 2016, CSWC entered into a senior secured credit facility (the “Corporate Credit Facility”) to provide additional liquidity to support its investment and operational activities. Borrowings under the Corporate Credit Facility accrued interest on a per annum basis at a rate equal to the applicable SOFR rate plus 2.15%. On September 2, 2026, the Company entered into the Fourth Amended and Restated Senior Secured Revolving Credit Agreement (the “Amendment”). Borrowings under the Corporate Credit Facility accrue interest at a rate equal to the applicable Term SOFR plus 2.00% per annum. The Amendment (1) increased commitments under the Corporate Credit Facility from $510 million to $595 million from a diversified group of lenders, (2) increased the uncommitted accordion feature that could increase the maximum commitments from up to $750 million to up to $1 billion, (3) extended the revolving period from August 2, 2027 to September 2, 2030 and extended final maturity from August 2, 2028 to September 2, 2031, (4) reduced the unused commitment fees from a range of (i) 0.50%-1.00% to (ii) 0.50%-0.75% per annum, based on utilization, on the unused lender commitments; and (5) amended certain financial covenants. In connection with the Amendment, the Company recognized a realized loss on extinguishment of debt of $1.1 million during the three months ended September 30, 2026, which was equal to the write-off of the related unamortized debt issuance costs.

Capital Southwest SPV LLC (“SPV”) is a wholly owned special purpose vehicle that was formed to hold investments for the SPV Credit Facility to support our investment and operating activities. On March 20, 2024, SPV entered into a special purpose vehicle financing credit facility (the “SPV Credit Facility”). The SPV Credit Facility included an initial commitment of $150 million. Pursuant to the terms of the loan agreement, on June 20, 2024, total commitments automatically increased from $150 million to $200 million. The SPV Credit Facility also includes an accordion feature that allows increases up to $400 million of total commitments from new and existing lenders on the same terms and conditions as the existing commitments. Borrowings under the SPV Credit Facility bear interest at three-month Term SOFR plus 2.50% per annum during the revolving period ending on March 20, 2027 and three-month Term SOFR plus an applicable margin of 2.85% thereafter. SPV (i) paid unused commitment fees of 0.10% through April 20, 2024 and (ii) pays unused commitment fees of 0.35% thereafter, on the unused lender commitments under the SPV Credit Facility, in addition to other customary fees. Under the SPV Credit Facility, SPV also pays a utilization fee based on the amount of borrowings utilized. The SPV Credit Facility matures on March 20, 2029.

In September 2026, the Company issued $350 million in aggregate principal amount of 6.750% Notes due 2031 (the “September 2031 Notes”). The September 2031 Notes were issued at a price of 98.985% of the aggregate principal amount of the September 2031 Notes, resulting in yield-to-maturity of 6.994%. The September 2031 Notes mature on September 15, 2031 and may be redeemed in whole or in part at any time prior to August 15, 2031, at par plus a “make-whole” premium, and thereafter at par. The September 2031 Notes bear interest at a rate of 6.750% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2027. In connection with the September 2031 Notes, the Company has entered into an interest rate swap. Under the interest rate swap, the Company receives a fixed interest rate of 6.75% and pays a floating interest rate of Daily Compounded SOFR plus 2.1587%.

The Company has an “at-the-market” offering (the “Equity ATM Program”), pursuant to which the Company may offer and sell, from time to time through sales agents, up to $2 billion of shares of its common stock. During the quarter ended September 30, 2026, the Company sold 2,732,562 shares of its common stock under the Equity ATM Program at a weighted-average price of $24.50 per share, raising $67.0 million of gross proceeds. Net proceeds were $66.0 million after commissions to the sales agents on shares sold. As of September 30, 2026, the Company has $999.3 million available under the Equity ATM Program.

Our wholly owned subsidiaries, Capital Southwest SBIC I, LP (“SBIC I”) and Capital Southwest SBIC II, LP (“SBIC II” and together with SBIC I, the “SBIC Subsidiaries”), each received a license from the Small Business Administration (the “SBA”) to operate as a Small Business Investment Company (“SBIC”) under Section 301(c) of the Small Business Investment Act of 1958, as amended, on April 20, 2021 and April 17, 2025, respectively. The SBIC licenses allow the SBIC Subsidiaries to obtain leverage by issuing SBA-guaranteed debentures (“SBA Debentures”), subject to the issuance of a leverage commitment by the SBA. SBA Debentures are loans issued to an SBIC that have interest payable semi-annually and a ten-year maturity. The interest rate is fixed shortly after issuance at a market-driven spread over U.S. Treasury Notes with ten-year maturities. For two or more SBICs under common control, the maximum amount of outstanding SBA Debentures cannot exceed $475 million. As of September 30, 2026, SBIC I had a total leverage commitment from the SBA in the amount of $175.0 million. During the quarter ended September 30, 2026, SBIC I repaid $16.0 million of debentures, resulting in a realized loss on extinguishment of debt of $0.3 million. As of September 30, 2026, SBIC I had $159.0 million of debentures outstanding. In September 2026, SBIC II received approval from the SBA to increase its leverage commitment from $175.0 million to $250.0 million, pursuant to recent legislation. As of September 30, 2026, SBIC II had a total leverage commitment from the SBA in the amount of $175.0 million, of which $130.0 million was drawn.

Share Repurchase Program

On July 28, 2021, the Company’s Board of Directors (the “Board”) approved a share repurchase program authorizing the Company to repurchase up to $20 million of its outstanding shares of common stock in the open market at certain thresholds below its NAV per share, in accordance with guidelines specified in Rules 10b5-1(c)(1)(i)(B) and 10b-18 under the Securities Exchange Act of 1934, as amended. On August 31, 2021, the Company entered into a share repurchase agreement, which became effective immediately, and the Company will cease purchasing its common stock under the share repurchase program upon the earlier of, among other things: (1) the date on which the aggregate purchase price for all shares equals $20 million including, without limitation, all applicable fees, costs and expenses; or (2) upon written notice by the Company to the broker that the share repurchase agreement is terminated. During the quarter ended September 30, 2026, the Company did not repurchase any shares of the Company’s common stock under the share repurchase program.

Regular Quarterly Dividend of $0.58 Per Share and Supplemental Quarterly Dividend of $0.06 Per Share for Quarter Ended December 31, 2026

On August 27, 2026, the Board declared a regular quarterly dividend of $0.58, of which $0.1934 per share will be paid in each of October, November and December 2026 and a supplemental quarterly dividend of $0.06 per share payable in December 2026, each of which is detailed in the table below.

The Company’s regular quarterly dividend for the quarter ending December 31, 2026 will be payable as follows:

Declared	Ex-Dividend Date	Record Date	Payment Date	Amount Per Share
8/27/2026	10/15/2026	10/15/2026	10/30/2026	$0.1934
8/27/2026	11/13/2026	11/13/2026	11/30/2026	$0.1934
8/27/2026	12/15/2026	12/15/2026	12/31/2026	$0.1934

The Company’s supplemental quarterly dividend for the quarter ending December 31, 2026 will be payable as follows:

Declared	Ex-Dividend Date	Record Date	Payment Date	Amount Per Share
8/27/2026	12/15/2026	12/15/2026	12/31/2026	$0.06

Total Regular Dividends per Share for Quarter Ending December 31, 2026:	$0.58
Total Supplemental Dividend per Share for Quarter Ending December 31, 2026:	$0.06
Total Dividends per Share for Quarter Ending December 31, 2026:	$0.64

When declaring dividends, the Board of Directors reviews estimates of taxable income available for distribution, which may differ from net investment income under generally accepted accounting principles. The final determination of taxable income for each year, as well as the tax attributes for dividends in such year, will be made after the close of the tax year.

Capital Southwest maintains a dividend reinvestment plan (“DRIP”) that provides for the reinvestment of dividends on behalf of its registered stockholders who hold their shares with Capital Southwest’s transfer agent and registrar, Equiniti Trust Company. Under the DRIP, if the Company declares a dividend, registered stockholders who have opted into the DRIP by the dividend record date will have their dividend automatically reinvested into additional shares of Capital Southwest’s common stock. 

Second Quarter 2027 Earnings Results Conference Call and Webcast

Capital Southwest has scheduled a conference call on Tuesday, November 3, 2026, at 11:00 a.m. Eastern Time to discuss the second quarter 2027 financial results. You may access the call by using the Investor Relations section of Capital Southwest’s website at www.capitalsouthwest.com, or by using http://edge.media-server.com/mmc/p/eirjpwcv.

An audio archive of the conference call will also be available on the Investor Relations section of Capital Southwest’s website.

For a more detailed discussion of the financial and other information included in this press release, please refer to the Capital Southwest’s Quarterly Report on Form 10-Q for the fiscal year ended September 30, 2026 to be filed with the Securities and Exchange Commission (the “SEC”) and Capital Southwest’s Second Fiscal Quarter 2027 Earnings Presentation to be posted on the Investor Relations section of Capital Southwest’s website at www.capitalsouthwest.com.

About Capital Southwest

Capital Southwest Corporation (Nasdaq: CSWC) is a Dallas, Texas-based, internally managed business development company with approximately $2.4 billion in investments at fair value as of September 30, 2026. Capital Southwest is a middle market lending firm focused on supporting the acquisition and growth of middle market businesses with $5 million to $50 million investments across the capital structure, including first lien, second lien and non-control equity co-investments. As a public company with a permanent capital base, Capital Southwest has the flexibility to be creative in its financing solutions and to invest to support the growth of its portfolio companies over long periods of time.

Forward-Looking Statements

This press release contains historical information and forward-looking statements with respect to the business and investments of Capital Southwest, including, but not limited to, the statements about Capital Southwest’s future performance and financial performance and financial condition, and the timing, form and amount of any distributions or supplemental dividends in the future. Forward-looking statements are statements that are not historical statements and can often be identified by words such as “will,” “believe,” “expect” and similar expressions and variations or negatives of these words. These statements are based on management’s current expectations, assumptions and beliefs. They are not guarantees of future results and are subject to numerous risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statement. These risks include risks related to: changes in the markets in which Capital Southwest invests; changes in the financial, capital, and lending markets; changes in the interest rate environment and its impact on our business and our portfolio companies; regulatory changes; tax treatment; our ability to operate the SBIC Subsidiaries as small business investment companies; the uncertainty associated with the imposition of tariffs and trade barriers and changes in trade policy and its impact on our portfolio companies and our financial condition; the impact of geopolitical conditions on our portfolio companies and opportunities available to us; an economic downturn or recession and its impact on the ability of our portfolio companies to operate and the investment opportunities available to us; the impact of supply chain constraints on our portfolio companies; and the elevated levels of inflation and its impact on our portfolio companies and the industries in which we invests.

Readers should not place undue reliance on any forward-looking statements and are encouraged to review Capital Southwest’s Annual Report on Form 10-K for the year ended March 31, 2026 and any subsequent filings with the SEC, including the “Risk Factors” sections therein, for a more complete discussion of the risks and other factors that could affect any forward-looking statements. Except as required by the federal securities laws, Capital Southwest does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.

Investor Relations Contact:

Michael S. Sarner, President and Chief Executive Officer
214-884-3829

CAPITAL SOUTHWEST CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES
(In thousands, except shares and per share data)
		September 30,				March 31,
			2026				2026
		(Unaudited)
Assets
Investments at fair value:
Non-control/Non-affiliate investments (Cost: $1,961,915 and $1,689,152, respectively)		$	1,951,314			$	1,682,425
Affiliate investments (Cost: $371,122 and $338,124, respectively)			359,192				340,760
Control investments (Cost: $126,051 and $92,208, respectively)			99,623				74,261
Total investments (Cost: $2,459,088 and $2,119,485, respectively)			2,410,129				2,097,446
Cash and cash equivalents			47,977				29,045
Restricted cash			4,480				400
Receivables:
Dividends and interest			38,749				31,678
Escrow			613				612
Other			5,818				2,190
Income tax receivable			279				717
Debt issuance costs (net of accumulated amortization of $15,637 and $13,172, respectively)			8,723				6,870
Other assets			7,974				8,560
Total assets		$	2,524,742			$	2,177,518
Liabilities
SBA Debentures (net of $7,336 and $5,333, respectively, of unamortized debt issuance costs)		$	281,664			$	217,667
2029 Convertible Notes (net of $4,674 and $5,413, respectively, of unamortized debt issuance costs)			225,326				224,587
September 2030 Notes (net of $5,355 and $6,029, respectively, of unamortized debt issuance costs)			344,645				343,971
September 2031 Notes (net of $7,883 and $0, respectively, of unamortized debt issuance costs)			337,866				—
Credit Facilities			195,000				345,000
Other liabilities			19,743				21,629
Accrued restoration plan liability			519				529
Income tax payable			1,757				636
Deferred tax liability			11,792				12,507
Total liabilities			1,418,312				1,166,526
Commitments and contingencies (Note 12)
Net Assets
Common stock, $0.25 par value: authorized, 135,000,000 shares at September 30, 2026 and 75,000,000 shares at March 31, 2026; issued, 66,491,300 shares at September 30, 2026 and 60,577,181 shares at March 31, 2026			16,623				15,144
Additional paid-in capital			1,203,681				1,074,854
Total distributable (loss) earnings			(113,874	)			(79,006	)
Total net assets			1,106,430				1,010,992
Total liabilities and net assets		$	2,524,742			$	2,177,518
Net asset value per share (66,491,300 shares outstanding at September 30, 2026 and 60,577,181 shares outstanding at March 31, 2026)		$	16.64			$	16.69

CAPITAL SOUTHWEST CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except shares and per share data)
		Three Months Ended								Six Months Ended
		September 30,								September 30,
			2026				2025				2026				2025
Investment income:
Interest income:
Non-control/Non-affiliate investments		$	47,216			$	40,746			$	89,613			$	81,984
Affiliate investments			7,445				6,831				14,640				12,087
Control investments			443				681				1,317				1,302
Payment-in-kind interest income:
Non-control/Non-affiliate investments			3,395				1,673				7,352				3,749
Affiliate investments			1,051				912				1,924				1,865
Control investments			535				209				617				440
Dividend income:
Non-control/Non-affiliate investments			608				52				775				1,660
Affiliate investments			345				2,690				1,556				4,735
Control investments			1,039				—				1,297				24
Fee income:
Non-control/Non-affiliate investments			3,883				1,740				7,191				3,136
Affiliate investments			473				770				870				959
Control investments			29				23				56				46
Other income			696				618				998				905
Total investment income			67,158				56,945				128,206				112,892
Operating expenses:
Compensation			3,240				2,631				5,939				6,587
Share-based compensation			1,937				1,270				3,385				2,413
Interest			20,981				16,020				39,480				31,284
Professional fees			1,963				1,341				3,427				2,551
General and administrative			1,871				1,666				3,841				3,323
Total operating expenses			29,992				22,928				56,072				46,158
Income before taxes			37,166				34,017				72,134				66,734
Federal income, excise and other taxes			678				1,149				1,121				2,248
Deferred taxes			196				884				(958	)			613
Total income tax provision			874				2,033				163				2,861
Net investment income		$	36,292			$	31,984			$	71,971			$	63,873
Realized gain (loss)
Non-control/Non-affiliate investments		$	3,734			$	3,485			$	4,067			$	21,331
Affiliate investments			3				(7,652	)			71				(3,565	)
Income tax provision			(588	)			(759	)			(1,547	)			(6,988	)
Total net realized gain (loss) on investments, net of tax			3,149				(4,926	)			2,591				10,778
Net unrealized (depreciation) appreciation on investments
Non-control/Non-affiliate investments			(7,891	)			(12,146	)			(3,873	)			(34,208	)
Affiliate investments			(3,120	)			10,757				(14,566	)			11,815
Control investments			(5,650	)			1,010				(8,481	)			(2,166	)
Income tax benefit (provision)			66				(1,058	)			(65	)			2,530
Total net unrealized (depreciation) appreciation on investments, net of tax			(16,595	)			(1,437	)			(26,985	)			(22,029	)
Net realized and unrealized (losses) gains on investments			(13,446	)			(6,363	)			(24,394	)			(11,251	)
Realized loss on extinguishment of debt			(1,410	)			—				(1,410	)			—
Realized loss on disposal of fixed assets			—				(2	)			—				(2	)
Net increase in net assets from operations		$	21,436			$	25,619			$	46,167			$	52,620
Pre-tax net investment income per share – basic		$	0.58			$	0.61			$	1.14			$	1.21
Net investment income per share – basic		$	0.56			$	0.57			$	1.14			$	1.16
Net increase in net assets from operations – basic		$	0.33			$	0.46			$	0.73			$	0.95
Net increase in net assets from operations – diluted		$	0.33			$	0.44			$	0.73			$	0.92
Weighted average common shares outstanding – basic			63,648,525				55,544,095				62,401,982				54,536,084
Weighted average common shares outstanding – diluted			73,036,538				64,830,413				71,777,799				63,809,345

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present and participate in one-on-one meetings at the following upcoming investor conferences in November:

Guggenheim 3^rd Annual Healthcare Innovation Conference
Date: Tuesday, November 10
Fireside chat: 2:00 PM ET

UBS Global Biopharma Conference
Date: Monday, November 16
Fireside chat: 12:00 PM GMT

2026 Jefferies Global Healthcare Conference in London
Date: Tuesday, November 17

Webcasts for the fireside chats will be available through the Events and Presentations section of Assembly Bio’s website at: https://investor.assemblybio.com/events-presentations. Replays will be accessible following the events.

About Assembly Biosciences
Assembly Biosciences is a biotechnology company developing innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesviruses, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV). For more information, visit assemblybio.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead, including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, including studies conducted by Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of product candidates; clinical and nonclinical data may not differentiate product candidates from other companies’ candidates; Assembly Bio’s ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, and other business operations; potential effects of changes in government regulation; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Investors:
Patrick Till
Meru Advisors
(484) 788-8560
investor_relations@assemblybio.com

Media:
Mike Beyer
Sam Brown LLC
(312) 961-2502
ASMBMedia@sambrown.com

WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Guggenheim Healthcare Innovation Conference
Fireside Chat
November 9, 2026 at 8:30am ET

Stifel 2026 Healthcare Conference
Fireside Chat
November 10, 2026 at 2:00pm ET

Live webcasts and replays, when available, can be found under “News / Events” in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

For media and investor inquiries
Jonathan Neely
VP, Head of Investor Relations
jneely@avalotx.com 

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com 

LOS ANGELES, Nov. 02, 2026 (GLOBE NEWSWIRE) — EVgo Inc. (“EVgo”) (NASDAQ: EVGO), one of the nation’s largest providers of public fast charging infrastructure for electric vehicles, today announced that its Board of Directors (“Board”) received an unsolicited and non-binding proposal (“Proposal”) from LS Power Equity Advisors, LLC and certain of its affiliates (collectively, “LS Power”) to acquire all of the outstanding shares of EVgo’s Class A common stock not currently owned by LS Power for cash consideration of $2.00 per share. LS Power currently holds approximately 56% of the combined voting power of EVgo’s outstanding common stock. A copy of the Proposal is available as an exhibit to EVgo’s Current Report on Form 8-K, which will be filed today with the Securities and Exchange Commission.

The Board has established a special committee composed of independent and disinterested directors to review and evaluate the Proposal. The special committee is authorized to retain independent advisors, including independent legal and financial advisors, to assist it in its work. No decisions have been made with respect to EVgo’s response to the Proposal. There can be no assurance that any definitive agreement relating to any proposed transaction will be executed or as to the terms thereof, or that any transaction will be approved or consummated. EVgo does not intend to comment further or disclose any developments regarding the Proposal unless and until it deems further disclosure is appropriate or required. EVgo’s shareholders do not need to take any action at this time.

About EVgo

EVgo Inc. (NASDAQ: EVGO) is one of the nation’s largest and most highly utilized public fast charging providers. With more than 1,200 fast charging locations across 47 states, EVgo makes charging part of everyday life by partnering with leading businesses including retailers, grocery stores, rideshare operators and autonomous vehicle companies. EVgo is scaling nationwide, strategically deploying high-power chargers, including EVgo Superchargers, across the U.S. At its dedicated Innovation Lab, EVgo is developing its next-generation chargers, performing extensive interoperability testing and collaborating with leading automakers and industry partners to advance the EV charging industry and deliver a seamless charging experience. 

Caution Concerning Forward Looking Statements

This press release contains forward-looking statements that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual events or results to differ from expectations contemplated by forward-looking statements include, among other things: risks and uncertainties relating to the unsolicited and non-binding take private proposal received from LS Power to acquire all of the outstanding shares of EVgo’s Class A common stock not currently owned by LS Power, including the possibility that any such transaction may not be pursued, approved, or consummated on the proposed terms, within any anticipated timeframe, or at all; the special committee’s review and evaluation of the Proposal; the effect of the announcement of the Proposal on EVgo’s business, stock price and relationships with customers, partners and employees; the risk of litigation relating to the Proposal or any proposed transaction; and those described under the heading “Risk Factors” and elsewhere in our most recent Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K filed with the Securities and Exchange Commission. Forward-looking statements are based on EVgo’s management’s current assumptions, expectations, and beliefs and are not guarantees of future performance. In light of these risks, uncertainties, and assumptions, actual results could differ materially and adversely from those anticipated or implied by the forward-looking statements. You should not rely on forward-looking statements as predictors of future results. Any forward-looking statements in this release are based on the limited information currently available to EVgo as of the date hereof, which is subject to change, and EVgo does not undertake any obligation to update these statements, even if new information becomes available in the future.

CONTACT: Contacts

For Investors:

investors@evgo.com

For Media:

press@evgo.com